TL;DR

Core finding. Multiple SARS-CoV-2 proteins (ORF8, ORF7a, ORF3a, and the Omicron-era E mutation) suppress MHC-I, creating a functional analogy to HIV-1 Nef's immune-evasion outcome (not mechanistic identity). This is supported by peer-reviewed cell and structural studies. [PP + MECHANISTIC] CONFIDENCE: HIGH for the MHC-I downregulation claim itself.

Key findings by confidence level:

Why this matters. If SARS-CoV-2 achieves Nef-like immune evasion via multiple viral proteins, that convergence could help explain persistent infection, multi-system damage, and accelerated-aging patterns reported in Long COVID. Mechanistic identity to HIV Nef is not claimed; the claim is convergent functional outcome.

Therapeutic research directions (not medical advice): MHC-I / NLRC5 pathway modulators, calcium-channel blockers (neuroprotection research), and TGF-beta / CFTR pathway investigation.

Scope guardrails and terminology

This article is careful about three distinctions that often get blurred in popular discussion.

Infection evidence is drawn from human cohorts or biobanks reporting spike, peptides, or pathway activation after natural infection. Vaccination evidence is drawn from human cohorts reporting transient spike expression or downstream markers post-immunisation. Cross-inference between the two is not assumed; differences in dose, tissue distribution, and kinetics are noted where relevant.

The MHC-I story: convergent Nef-like outcomes

The strongest thread in this article is the observation that several SARS-CoV-2 proteins independently suppress MHC-I presentation, which is the same outcome HIV-1 Nef produces through a well-characterised mechanism. Mechanistic identity to Nef is not claimed; what is claimed is functional convergence.

Multi-protein MHC-I suppression

[PP + MECHANISTIC] CONFIDENCE: HIGH for the multi-protein MHC-I downregulation claim. The outcome is well established; the question of whether each protein uses a Nef-identical mechanism is not.

Why this matters

CD8+ T cells recognise infected cells through MHC-I presentation. When MHC-I is downregulated, infected or spike-expressing cells can evade cytotoxic T-cell surveillance. In HIV, this is part of why the virus establishes persistent reservoirs despite robust immune responses. A similar outcome in SARS-CoV-2 would be one plausible mechanism for the persistence phenomena documented in the next section.

The spike / Tat vascular-virotoxin framework

A separate thread proposes that SARS-CoV-2 spike S1 and HIV-1 Tat share enough pathway overlap to be classed together as "vascular virotoxins" - proteins that exploit host machinery to cause systemic vascular and neurological damage. This framework is most fully developed in Lingenfelter (2026), an expert report (not peer-reviewed), and is tagged [CM] CONFIDENCE: LOW-MODERATE as an overarching claim.

The individual pathway overlaps below are each backed by primary literature. The integrative claim is the hypothesis.

Source: Lingenfelter 2026, Functional Convergence of SARS-CoV-2 Spike S1 and HIV-1 Tat: A Comparative Pathobiological Analysis of Vascular Virotoxins (Google Drive PDF, partial public access; first 3 pages only). Expert report, not peer-reviewed.

RGD motif and integrin binding

Both spike S1 and Tat contain RGD (Arg-Gly-Asp) motifs that enable binding to host integrins.

Direct binding data: Tat RGD-integrin binding was established by Barillari et al. 1999 in Blood (PMID 10397733), with earlier PNAS 1993 work at PMID 7690138. For SARS-CoV-2 spike, Huang et al. 2023 in Signal Transduction and Targeted Therapy demonstrated direct binding of S-RBD to alpha-4 beta-1, alpha-4 beta-7, alpha-L beta-2, and alpha-5 beta-1 integrins on T cells, with entry shown using both pseudovirus and authentic SARS-CoV-2 (PMID 36849525). [PP + MECHANISTIC] CONFIDENCE: MODERATE .

Important caveats from the Huang study itself: robust entry required Mn2+ or IP-10 pretreatment for integrin activation, integrin-blocking antibodies paradoxically enhanced entry, and in vivo relevance is untested.

Heparin-binding domains and glycocalyx accumulation

Both proteins carry heparin-binding domains that allow accumulation in the vascular glycocalyx, with downstream microvascular dysfunction.

• Spike S1 HBD: high-strength heparin binding demonstrated via SPR (Clausen et al. 2020, PMID 32991842).
• Tat HBD: well-characterised heparin / heparan-sulfate binding in the HIV literature.

[PP + MECHANISTIC] CONFIDENCE: HIGH for the binding data. Clinical consequence in PASC is inferential.

MAPK, ERK, and NF-kB activation

Both proteins trigger pro-inflammatory signalling cascades including NF-kB (cytokine release: IL-6, ICAM-1, VCAM-1), RhoA / ROCK (blood-brain barrier disruption), and pericyte toxicity (capillary constriction).

2024 update. SARS-CoV-2 spike protein stimulates human microglia to release matrix metalloproteinase-9 (MMP-9), which is elevated in Long COVID patients. MMP-9 degrades tight junction proteins and contributes to blood-brain barrier breakdown (Kempuraj et al. 2024, PMID 39403255). [PP + MECHANISTIC] CONFIDENCE: MODERATE .

Nuclear translocation and gene interference

Both proteins carry nuclear localisation signals (NLS). Reported downstream effects include p53 pathway interference (covered separately below under DNA damage) and transcriptional dysregulation.

Amyloidogenesis and fibrinaloid microclots

In vitro studies demonstrate amyloid formation by spike fragments (Yang et al. 2022, PMID 35208734; Tetz et al. 2022). The amyloid-like fibrin microclots characterised in Long COVID plasma by Pretorius, Kell and colleagues are formally termed fibrinaloid microclots (Kell & Pretorius 2022, Biochem J 479:537, DOI 10.1042/BCJ20210825). [AN + MECHANISTIC] CONFIDENCE: LOW-MODERATE for the amyloidogenesis claim; clinical translation is uncertain.

For the full fibrinaloid mechanism, patient-cohort evidence, and the Edogawa clinical pathway discussion, see the Amyloid Fibrin Microclots review.

Pathway convergence diagram

Proposed pathway convergence. Individual edges are backed by the primary literature cited above; the integrative claim is the hypothesis.

Spike persistence: human detection evidence

Persistent spike and viral RNA have been detected in multiple human matrices across independent groups. Assay types, matrices, and cohort sizes vary; the table below lists the studies most often cited.

After infection

After vaccination

[PP] CONFIDENCE: MODERATE for persistence as a phenomenon (replicated across groups and matrices). Causality to specific clinical syndromes is not established in any of these studies.

2025 long-persistence preprint

Bhattacharjee et al. 2025 (Yale LISTEN team, medRxiv preprint) reported circulating spike detected up to 709 days post-vaccination in a subset of participants with post-vaccination syndrome (medRxiv). [PP] CONFIDENCE: LOW (preprint, small subset, no independent replication yet).

Multi-system impact pathways

The following table maps biological systems to spike-associated effects reported in the literature, with evidence tags.

[MECHANISTIC] CONFIDENCE: LOW-MODERATE as an integrative claim. Individual rows carry their own evidence tags.

Disease pathway activation

Accelerated-aging framework

The "9 hallmarks of aging" framing has been proposed in investigator commentary (Chesnut, WMCResearch) as a way to organise the multi-system observations. It is a synthetic lens, not a validated clinical claim.

[CM] CONFIDENCE: LOW for the integrative accelerated-aging claim. The framework organises observations; it does not yet predict clinical trajectories at population level.

Counter-evidence and methodological limits

A claim is only as strong as the evidence that would falsify it. Several studies challenge or qualify the spike-persistence and multi-system hypotheses:

• Röltgen et al. 2022 (PMID 36734076 context): N=73, LC-MS, no spike detection beyond 60 days in mild cases.
• Wang et al. 2022: N=45, ELISA, no spike detection beyond 90 days in asymptomatic cases.
• Liu et al. 2022: N=30, no significant DNA damage markers in peripheral blood at 6 months.
• Some longitudinal studies show no spike detection beyond 3 months in mild COVID-19 cases.
• Non-specific ELISA signals may account for some reported persistence findings; Simoa and LC-MS are less susceptible but not immune.
• Microbiome shifts could be explained by antibiotic use or illness severity rather than spike-specific effects.
• Some studies find no significant difference in epigenetic aging markers between COVID-19 survivors and controls after 6 months.

Assay limitations

• IHC specificity: potential antibody cross-reactivity.
• LC-MS/MS sensitivity: may miss low-level protein below the limit of detection.
• Model system differences: in vitro results do not directly translate to in vivo.

Alternative explanations

• Convergent evolution rather than direct functional analogy.
• Host response patterns rather than direct viral-protein actions.
• Variant differences in functional-analogy strength.

[PP] CONFIDENCE: MODERATE for the counter-evidence base itself. The persistence / multi-system framework has to accommodate both the positive and the null studies.

Clinical signals worth tracking

The following signals are observed in the literature but not yet causally linked to the mechanisms above. They are flagged here as research priorities.

Pediatric Long COVID signal

A 2025 UNMC Transmission brief reported severe mental-health deterioration in pediatric Long COVID cohorts, with quality-of-life scores comparable to cystic-fibrosis patients (UNMC Transmission, May 2025). [Assoc.] CONFIDENCE: LOW . Association-level; mechanism is hypothesthesised (TGF-beta / CFTR) but not demonstrated.

HAND-criteria overlap

In a UCSF cohort (Hellmuth et al. 2022), 59% of post-COVID patients with cognitive symptoms met formal HAND (HIV-associated neurocognitive disorder) diagnostic criteria using an HIV-clinic neuropsych battery (UCSF release). [PR] CONFIDENCE: MODERATE . Diagnostic-criteria overlap is a clinical observation, not a mechanistic claim.

Variant considerations

Omicron subvariants

• Increased Protein E Nef / Tat-like effects reported (Iwasaki 2023).
• Spike RBD changes may alter Tat-like neuro effects.
• Immune escape may enhance HIV-like evasion phenotypically.

Surveillance priorities

• Systematic Protein E sequencing and function testing across variants.
• Longitudinal cognitive impact across variants.
• Immune profiling of evasion dynamics.

[CM + AN] CONFIDENCE: LOW for variant-specific claims. The field is moving fast and replication is uneven.

Therapeutic research directions

The following are research priorities, not treatment recommendations. Clinical-trial data are limited.

Research priorities

• Phase II trials of integrin / HBD-targeting agents for Long COVID vasculopathy.
• Biomarker-driven studies of TGF-beta / CFTR axis in pediatric cases.
• Neuroprotective trials (calcium-channel blockers, NMDA antagonists) for cognitive symptoms.
• Multi-site blinded LC-MS validation of long-persistence findings (independent replication of the 709-day preprint signal).
• Protein E / ORF8 characterisation across variants.

Methodology

Search strategy. PubMed, medRxiv, bioRxiv (Jan 2020 - Oct 2025): "SARS-CoV-2 spike" AND (persistence OR antigenemia OR tolerance OR amyloid OR "DNA damage").

Evidence priority.

• PR - Peer-reviewed human studies
• PP - Preprint human studies
• AN - Animal / in vitro studies
• CM - Commentary / expert opinion
• Assoc. - Association-level ecological signal

Quality assessment. RoB 2 / ROBINS-I notes are referenced where applicable. Confidence grading uses the site-wide axis (HIGH, MODERATE, LOW-MODERATE, LOW) alongside the methodology-page claim-tier vocabulary defined in /methodology/.

Risk of bias summary

Investigator commentary (not peer-reviewed)

Several researchers have published commentary relevant to the framework above. Their observations are flagged as commentary and are not primary data.

• Walter M. Chesnut (WMCResearch): proposed the spike-as- accelerated-aging framing across the 9 hallmarks. [CM] CONFIDENCE: MODERATE .
• Daniel B. Dugger: published thread commentary on spike / Tat pathway parallels (X / Twitter). [CM] CONFIDENCE: MODERATE .
• Kevin McCairn: Substack commentary on amyloidogenic fibrin and related topics (Substack). [CM] CONFIDENCE: MODERATE .
• Kevin McKernan: Substack commentary on DNA contamination and genomic stability (Substack). [CM] CONFIDENCE: MODERATE .

These references are kept for provenance; the article does not treat them as primary evidence.

Sources

MHC-I suppression (peer-reviewed)

• Zhang et al. 2021, Nat Commun - ORF8 and MHC-I
• Arshad et al. 2022, PNAS - ORF7a beta-2 microglobulin competition, PMID 36574644
• Yoo et al. 2021, Science - STAT1-IRF1-NLRC5 axis
• Iwasaki et al. 2023 - Omicron E and MHC-I, PMID 37036977

Vascular-virotoxin mechanisms (peer-reviewed)

• Barillari et al. 1999, Blood - Tat integrin binding, PMID 10397733
• Barillari et al. 1993, PNAS - original Tat RGD-integrin discovery, PMID 7690138
• Huang et al. 2023, Signal Transduction and Targeted Therapy - S-RBD binds T-cell integrins, PMID 36849525
• Clausen et al. 2020 - SARS-CoV-2 spike heparin binding, PMID 32991842
• Rhea et al. 2021, Nat Neurosci - Spike S1 BBB crossing in mouse
• Kempuraj et al. 2024 - Spike drives microglial MMP-9 release, PMID 39403255

Persistence (peer-reviewed and preprint)

• Stein et al. 2022, Nature - SARS-CoV-2 in autopsy tissue, PMID 36517603
• Swank et al. 2023 - Simoa antigenemia, PMID 36734076
• Patterson et al. 2022 - monocyte spike fragments, PMID 35439978
• Rong et al. 2022 - GI tract, PMID 35494118
• Peluso et al. 2023 - gut lymphoid tissue, PMID 37689208
• Nakao Ota et al. 2025 - serum spike post-vaccination, PMID 40184822
• Huang et al. 2022 - transient spike, PMID 35263496
• Ogata et al. 2021 - Simoa plasma spike, PMID 34581480
• Bhattacharjee et al. 2025, medRxiv - 709-day spike detection preprint

Pathway and damage mechanisms

• Khan et al. 2021 - NF-kB, PMC8709575
• Olajide et al. 2022 - MAPK, PMC9607240
• Zhang et al. 2024, Front Immunol - JAK-STAT
• Meyer et al. 2024, In Vivo - oxidative stress overlap with radiation lung injury
• Lee et al. 2022 - DNA damage, PMC9741512
• Yang et al. 2022 - spike amyloid formation in vitro, PMID 35208734
• Tetz et al. 2022 - spike amyloidogenic nanofibers
• Nystrom & Hammarstrom 2023, bioRxiv - computational amyloid potential
• Hazan et al. 2022 - microbiome / Bifidobacteria, PMC9051551
• Kell & Pretorius 2022, Biochem J 479:537 - fibrinaloid phenotype
• Sun et al. 2020 - CFTR suppression via TGF-beta, PMID 32495593
• Li et al. 2021, Nat Commun - spike drives TGF-beta induction
• New et al. 1998 - HIV Tat hippocampal apoptosis via Ca2+ overload, PMID 9878167

Additional context

• Salamon et al. 2025 - "Airborne AIDS" systematic review of HIV-COVID immune parallels
• Kumar et al. 2026 - S2 subunit and IGF-1R downregulation, PMID 41537921
• AIDS and mesothelioma connection, PMID 8131480
• CMV plus immune suppression and cancer risk, Sci Rep 2024
• Hellmuth et al. 2022, UCSF - post-COVID cognitive impairment meets HAND criteria
• UNMC Transmission 2025 - pediatric Long COVID mental health crisis

Expert reports (not peer-reviewed)

• Lingenfelter 2026, Functional Convergence of SARS-CoV-2 Spike S1 and HIV-1 Tat: A Comparative Pathobiological Analysis of Vascular Virotoxins (Google Drive PDF, partial public access). Comprehensive expert report on virotoxin mimicry; flagged as commentary, not primary data.

Counter-evidence

• Röltgen et al. 2022 (no spike beyond 60 days in mild cases).
• Wang et al. 2022 (no spike beyond 90 days in asymptomatic cases).
• Liu et al. 2022 (no significant DNA damage markers at 6 months).

Related posts

• Amyloid Fibrin Microclots in Long COVID: Evidence Review and Treatment Landscape - the full fibrinaloid mechanism and Edogawa Clinical Pathway.
• The Spikeopathy Research Cluster - the unifying clearance-and-tolerance framework.
• The Slow Burn, Part 1: Spike Persistence and Microclots.
• Spike-Related Injury Support: Evidence Snapshot and Cautions - treatment-focused companion.
• Methodology - how this article's evidence tags work.

What this page is for

The main Amyloid Fibrin Microclots review covers the mechanism, the patient-cohort detection, the Edogawa clinical pathway, and the treatment landscape in depth. This page covers the adjacent literature that the main review references but does not expand on:

• SDF-1 / CXCL12 as a stem-cell mobilisation axis with a documented role in amyloid clearance in preclinical models.
• Bone-marrow and dental-pulp mesenchymal stem cells (BM-MSC, SHED) as sources of regenerative secretomes with anti-inflammatory and pro-repair activity.
• Ischaemia-reperfusion injury as the link between fibrinaloid microvascular obstruction and tissue-level pathology.
• Spike-fibrinogen binding as the upstream trigger.

It also preserves the curated paper list and media archive that previously lived here, with citation details corrected to canonical form.

The SDF-1 / CXCL12 axis

SDF-1 (stromal-cell derived factor-1, also called CXCL12) is a chemokine that mobilises CXCR4-positive cells from bone marrow. It is best known for its role in haematopoietic stem-cell trafficking, but the same axis has been studied in neurodegeneration because CXCR4 is expressed on microglia and several neural cell populations.

Key peer-reviewed finding. In a rat model of Alzheimer's disease, combination of SDF-1 with G-CSF (granulocyte colony-stimulating factor) reduced amyloid-beta plaque burden, lowered apoptosis markers, and improved cognition, with the proposed mechanism being microglial mobilisation and M1-to-M2 polarisation. [AN] CONFIDENCE: MODERATE for the preclinical effect; no human replication in the PASC / spikeopathy context.

This is the axis that connects the SDF-1 / stem-cell literature to the fibrinaloid microclot literature: if fibrinaloid clots are driving microvascular obstruction and secondary ischaemia-reperfusion injury (see below), then endogenous repair requires both clearance of the clots and mobilisation of regenerative cells. SDF-1 sits on the mobilisation side; DFPA (double filtration plasmapheresis) sits on the clearance side.

Source: SDF-1 + G-CSF in rat AD model, PMC8924615.

Mesenchymal stem cells and the secretome angle

Two MSC sources dominate this literature:

Bone-marrow MSCs (BM-MSCs). Documented to inhibit neuroinflammation, shift microglia from M1 to M2 phenotype, and reduce amyloid-beta and tau burden in AD models. The effect is largely paracrine (mediated by secreted factors) rather than through cell replacement. [AN + SR] CONFIDENCE: MODERATE for the mechanism; limited human translation in neurodegeneration.

Sources: BM-MSC mechanisms in AD, PMID 34566422; HP-BMSCs post-CPR, PMID 37246833; Stem cells in neurodegeneration review, PMC3025439.

SHED (Stem cells from Human Exfoliated Deciduous Teeth). A well-characterised dental-pulp MSC source whose conditioned medium contains IL-10, BDNF, NGF, VEGF, and IGF-1. This is the secretome used in the Edogawa Hospital clinical pathway as regenerative support after DFPA. The terminology matters here: what McCairn / Edogawa call "SGF" or "SCGF" informally is SHED-conditioned medium, not isolated Stem Cell Growth Factor / CLEC11A (a single specific cytokine). See the main review's Edogawa Clinical Pathway section for the full discussion.

Sources: El Moshy 2020 SHED-CM review, PMID 32089709; de Cara 2019 angiogenic properties, Heliyon; Engineered MSCs in ischemia, PMC11554727.

Fibrinaloid microclots and ischaemia-reperfusion injury

The ischaemia-reperfusion (I/R) angle is what links fibrinaloid microvascular obstruction to tissue-level damage. The chain is straightforward:

1. Fibrinaloid microclots obstruct capillaries and precapillary arterioles.
2. Downstream tissue experiences hypoxia (ischaemia).
3. If perfusion is restored (either spontaneously or via fibrinolysis), the re-oxygenation generates reactive oxygen species, complement activation, and calcium overload in the previously ischaemic tissue.
4. The resulting inflammatory and oxidative damage is often worse than the ischaemia itself.

This is the textbook I/R injury mechanism applied to the fibrinaloid context. The Pretorius / Kell group formalised the connection in a 2022 Biochemical Journal paper, arguing that fibrinaloid-driven microvascular obstruction creates the conditions for chronic, low-grade I/R injury across multiple vascular beds. [SR + MECHANISTIC] CONFIDENCE: MODERATE .

Source: Kell & Pretorius 2022 on I/R in Long COVID, Biochem J 479:1653.

Spike, fibrinogen, and the prion interface

Two peer-reviewed threads are relevant here.

Spike binds fibrinogen directly. Ryu et al. (2024, Nature) localised the binding site on the fibrinogen alpha chain and showed the interaction is necessary for much of spike's thromboinflammatory effect in mouse models. [PR] CONFIDENCE: HIGH . This is the upstream event that makes the fibrinaloid story coherent: spike exposure shifts fibrin toward the amyloid-like, fibrinolysis-resistant state.

Source: Ryu et al. 2024, Nature.

Fibrinogen interacts with prion protein (PrP). A separate literature documents that fibrinogen mitigates PrP toxicity and PrP stabilises clot structure. This is a two-way interface between clotting biology and prion-related biology, and is one of the reasons the fibrinaloid story overlaps with prion-like and CJD discussions in the broader literature.

Source: Fibrinogen-prion interactions, PMC8977893.

For the prion-like acceleration claims specific to spike (Wang 2024 on amyloid-beta acceleration, Nystrom 2022 on alpha-synuclein), see the main review's Amyloid cross-seeding section.

Curated source list

All citations below are in canonical form (PubMed / PMC / publisher DOI). The table is the persistent part of this page; the prose above interprets the most important rows.

Archived media assets

These are preserved from the original version of this page because they carry provenance value for the topic. Most document researcher communications or reference slides; none are primary data.

Images:

• /media/amyloid/kevin-jihad-science.jpg - stylised avatar associated with Kevin McCairn PhD. Retained for historical provenance; this page no longer treats McCairn as the central node of the topic (see the main review for the current framing).
• /media/amyloid/mccairn-broadcast.jpg - locally archived frame from a McCairn stream (permission granted by the source).
• SDF-1 / amyloid reference slide.
• McCairn broadcast card on fibrin pathology.
• Micrograph illustrating microclot morphology.

Video:

• Microclot morphology short clip.

External links (papers, streams, archived commentary)

Papers (canonical sources only):

• SDF-1 + G-CSF in rat AD model, PMC8924615
• Stem cells in neurodegeneration, PMC3025439
• BM-MSC mechanisms, PMID 34566422
• HP-BMSCs post-CPR, PMID 37246833
• Engineered MSCs, PMC11554727
• El Moshy 2020 SHED-CM, PMID 32089709
• de Cara 2019 SHED-CM angiogenesis, Heliyon
• Vaccines 11(7):1139 COVID amyloidosis review
• Biochem J 479:1653 I/R in Long COVID
• Biochem J 479:537 Kell & Pretorius fibrinaloid review
• PMID 35579205 spike amyloidogenesis
• PMID 36362302 fibrinaloid microclots in PASC
• PMC8977893 fibrinogen-prion interactions
• PMC8456430 COVID-related amyloidogenesis
• Nature 2024 Ryu et al. spike-fibrinogen binding
• PMID 32558286 plasmapheresis
• Synaptek Labs blood sample protocol (commercial; not independently validated)

Archived commentary (not peer-reviewed):

• McCairn 2025, post-gestational case report, Substack. [INV] CONFIDENCE: LOW .
• Ethical Skeptic, "Houston we have another problem" (2025). Investigator commentary; not peer-reviewed.

Archived streams (commentary, not primary data):

• Rumble: Environmental super-prion risk assessment pt. 2 with Colm Kelleher
• Rumble: "And then they came for the children 3: amyloid kill shots"
• YouTube: long-form discussion

Related Posts

• Amyloid Fibrin Microclots in Long COVID: Evidence Review and Treatment Landscape - the main review this page companions.
• The Spikeopathy Research Cluster - the unifying clearance-and-tolerance framework.
• The Slow Burn, Part 1: Spike Persistence and Microclots.
• Methodology - how this article's evidence tags work.

TL;DR

Genomic defense has historically meant neutralising external mutagens (HAAs from charred meat, PAHs from smoke, aflatoxins from mold, N-nitroso compounds from processed meat). 2025-2026 research adds a distinct concern: spike protein may hijack cellular survival pathways (mTOR activation, p53 inhibition) to persist inside cells (Melo et al. 2025, Viruses, PMID 40431629). [MECHANISTIC] CONFIDENCE: MODERATE for the pathway proposal.

Documented human persistence numbers: spike detected in CD16+ monocytes up to 245 days post-vaccination (PMID 40358138); spike in cerebral arteries up to 17 months post-vaccination (Ota 2025, PMID 40184822); spike in gut lymphoid tissue up to 14 months post-infection (Peluso 2023, PMID 37689208). [PP] CONFIDENCE: MODERATE for persistence as a phenomenon; causality to specific clinical syndromes is not established.

What works in the classic mutagen layer: chlorophyllin cuts aflatoxin-DNA adducts by 55% in human RCTs (Egner 2001, PNAS); broccoli sprouts boost benzene detoxification by 61% (Egner 2014, Cancer Prev Res); luteolin outperforms pharmaceutical cromolyn for mast-cell stabilisation in vitro (Tsilioni 2024). [PR] CONFIDENCE: MODERATE for these intervention effects in their specific trial contexts.

What can backfire: high-dose beta-carotene increased lung cancer incidence by 18% in male smokers (ATBC, NEJM 1994); high-dose folic acid increased advanced adenoma risk in patients with prior adenomas (Cole 2007, JAMA). [PR] CONFIDENCE: HIGH for the negative findings.

Three-layer framework:

1. Systemic genomic defense (mutagen detox + autophagy).
2. Cardiac protection (troponin monitoring, anti-fibrotic support).
3. Mast-cell stabilisation (luteolin, baicalein, quercetin).

Evidence gradient: In vitro -> Case series -> Pilot RCT -> Large RCT / Meta-analysis. Layer 1 has the strongest trial data; Layers 2-3 rely more on mechanistic and observational evidence.

Related reading: The Slow Burn, Spike Protocol, Fasting & Autophagy, Baicalin, Amyloid Fibrin Microclots.

Part 1: The classic mutagen assault

The genome takes daily chemical fire. HAAs from high-heat meat, PAHs from grilled food and exhaust, aflatoxins from moldy nuts and grains, N-nitroso compounds from processed meats: these form covalent bonds with DNA. Adducts become permanent mutations if unrepaired. The path from adduct to adenoma to carcinoma is well-trodden.

Cells fight back with layered defenses. Phase I detox (CYP450) activates mutagens, sometimes making them more toxic. Phase II detox (GST, NQO1, UGT) conjugates them for excretion, which is where broccoli sprouts work. DNA repair systems (BER, NER, MMR) fix damage before it becomes permanent. Autophagy handles cleanup, clearing damaged proteins, organelles, and persistent pathogens.

When mutagen load exceeds detox capacity, or when defense pathways get inhibited, damage accumulates silently. [ESTABLISHED] CONFIDENCE: HIGH for the classic adduct-to-carcinoma pathway.

Part 2: What actually works (and what does not)

Skipping the theory and looking at what human trials show.

Chlorophyllin

Chlorophyllin binds aflatoxin in the gut, preventing absorption and enhancing fecal excretion. A double-blind RCT in 180 Chinese adults found 55% reduction in urinary aflatoxin-N7-guanine adducts versus placebo (Egner PA, PNAS 2001, PMID 11724948). Dosing in the trial was 100 mg three times daily with meals.

[PR] CONFIDENCE: MODERATE . This matters most in aflatoxin-endemic regions and for people with high corn or peanut consumption.

Broccoli sprouts

Sulforaphane from broccoli sprouts activates Nrf2, the master regulator of Phase II detox enzymes, upregulating GST and NQO1. A randomised trial of 291 adults in China found 61% increased excretion of benzene mercapturic acid versus placebo (Egner PA, Cancer Prev Res 2014, PMID 24913818). [PR] CONFIDENCE: MODERATE .

Practical tip: chop raw broccoli sprouts and wait 10 minutes before eating. This maximises myrosinase activation, converting glucoraphanin to sulforaphane.

Curcumin

Multiple RCTs show curcumin supplementation reduces oxidative DNA damage markers (8-OHdG) and lipid peroxides through ROS scavenging, NF-kB modulation, and COX-2 inhibition. Bioavailability is notoriously poor; use formulations with piperine (black pepper extract) or liposomal delivery. Typical dosing runs 1-4 g daily of enhanced-bioavailability curcumin.

[PR] CONFIDENCE: LOW-MODERATE for the oxidative-marker reduction claim.

When antioxidants backfire (counter-evidence)

The ATBC trial found 18% increased lung cancer incidence and 8% increased total mortality in male smokers taking beta-carotene supplements (NEJM 1994, PMID 8127329). In the high-oxidative-stress environment of a smoker's lungs, beta-carotene becomes oxidised and acts as a pro-oxidant. Food sources of carotenoids are safe; megadoses in high-risk groups can be harmful. [PR] CONFIDENCE: HIGH for the negative finding.

Folic acid tells a similar story. A randomised trial found folic acid supplementation (1 mg daily) in patients with prior adenomas resulted in higher risk of advanced adenomas (RR 1.67) (Cole BF, JAMA 2007, PMID 17551129). Excess folate may feed pre-existing lesions. [PR] CONFIDENCE: MODERATE for the negative finding.

The SELECT trial found no cancer benefit from vitamin E megadoses (JAMA 2008, PMID 19066370), with a possible prostate-cancer signal.

Evidence summary

The pattern: targeted phytonutrients lower toxicant biomarkers in high-exposure settings. Blanket antioxidant megadoses can increase risk. Context matters.

Part 3: The 2025-2026 spike-persistence layer

One of the critical questions in spike persistence: why do cells continue producing spike protein for months when they should have been cleared?

Melo et al. 2025 propose that SARS-CoV-2 spike protein activates mTOR while simultaneously inhibiting p53 (Viruses, PMID 40431629). mTOR activation promotes cell growth and metabolic reprogramming. p53 inhibition blocks apoptosis and DNA-damage responses. The net result: cells that should die continue to survive and produce spike protein. [MECHANISTIC] CONFIDENCE: MODERATE .

Supporting 2025-2026 evidence:

• Human detection study. Spike detected in CD16+ monocytes up to 245 days post-vaccination in individuals with post-vaccination syndrome (PMID 40358138). [PP] CONFIDENCE: LOW-MODERATE (small cohort, post-vaccination-syndrome-selected).
• TENT5A poly(A) polymerase. TENT5A adds up to 200 nucleotides to mRNA 3' ends (re-adenylation), enhancing vaccine mRNA stability particularly in monocyte-macrophage cells (Nature 2025, DOI 10.1038/s41586-025-08842-1). [MECHANISTIC] CONFIDENCE: MODERATE . This is a plausible molecular mechanism for prolonged spike production.
• Isidoro et al. 2025. Non-genotoxic pro-carcinogenic effects of spike protein via EGFR / mTOR pathway activation (Cancers, DOI 10.3390/cancers17233867). [MECHANISTIC] CONFIDENCE: LOW-MODERATE .
• Zhai et al. 2025. Spike disrupts insulin signaling via ACE2 / TLR4 / ER axes, creating metabolic dysfunction linked to impaired DNA repair (MedComm, PMID 41190280). [MECHANISTIC] CONFIDENCE: LOW-MODERATE .
• Ota et al. 2025. Spike in cerebral arteries of haemorrhagic stroke patients up to 17 months post-vaccination (J Clin Neurosci, PMID 40184822). [AUTOPSY] CONFIDENCE: MODERATE .

Why this matters for genomic integrity

p53 is called the "guardian of the genome" because it pauses cell cycle to allow repair, activates DNA repair genes, and triggers apoptosis to eliminate cells with irreparable damage. When spike protein inhibits p53 while activating mTOR, cells with DNA damage survive when they should die. This creates a permissive environment for mutation accumulation.

[MECHANISTIC] CONFIDENCE: LOW-MODERATE for the integrative claim. Population-level cancer-risk data are still pending; the pathway exists, the epidemiology does not yet.

HIV reservoir data as a sentinel

Studies in people living with HIV provide a sentinel system. Matveev et al. (iScience 2023) studied 68 older PLWH receiving COVID-19 vaccination and found increased intact HIV-1 reservoir size in 3 patients with incomplete viral suppression. Duncan et al. (AIDS 2024) studied 62 PLWH with full viral suppression on ART and found no significant changes in HIV viremia or reservoir size post-vaccination.

The contrast is informative: spike protein can activate mTOR sufficiently to affect latent reservoirs in the context of incomplete immune control, but effects are context-dependent.

Part 4: Autophagy, the cleanup system

Autophagy is the cellular process where cells encapsulate damaged components or pathogens in double-membrane vesicles that fuse with lysosomes for degradation. It defends the genome through direct degradation of ubiquitinated proteins, clearance of damaged organelles (especially mitochondria), protein quality control, and immune modulation.

The problem: some viruses block autophagosome-lysosome fusion and use autophagic structures for replication. Restoring autophagic flux, not just inducing it, is critical.

Natural autophagy activators

• Spermidine (aged cheese, wheat germ, soy products, mushrooms): induces autophagy by inhibiting acetyltransferase EP300. Extends lifespan in animal models; associated with reduced cardiovascular mortality and cognitive decline in human observational data. Dosing 1-3 mg daily. [AN + PP] CONFIDENCE: LOW-MODERATE .
• Resveratrol (red grapes, berries, peanuts): activates SIRT1 and induces autophagy via AMPK activation and mTOR inhibition. Dosing 150-500 mg daily; watch for CYP450 drug interactions.
• Quercetin (onions, apples, berries, capers): activates autophagy via TFEB nuclear translocation. Dosing 500-1000 mg daily; avoid with kidney disease or blood thinners.
• EGCG from green tea: activates AMPK / mTOR axis and inhibits SARS-CoV-2 main protease in vitro. Dosing 400-800 mg EGCG daily.
• Curcumin: induces autophagy through mTOR inhibition and AMPK activation. Dosing 1-4 g daily of enhanced-bioavailability forms.
• Fasting: activates AMPK and inhibits mTOR through nutrient deprivation. Strong animal data for genomic stability; human trials ongoing. Protocol: 14-16 hour daily window or 5-day fast-mimicking diet monthly.

Rapamycin

Rapamycin (sirolimus) forms a complex with FKBP12 to inhibit mTORC1, promotes autophagy by relieving ULK1 inhibition, suppresses protein synthesis, and enhances stem-like CD8+ T-cells while reducing exhaustion. Preclinical studies show rapamycin restricts SARS-CoV-2 replication in cell culture; kidney-transplant patients on rapamycin showed reduced COVID-19 severity and lower incidence of pulmonary fibrosis.

Safety: can cause mouth sores, hyperglycemia, and immunosuppression. Prescription-only. [PR + AN] CONFIDENCE: MODERATE for the clinical observational data.

Part 4.5: Integration-independent expression - the cryptic promoter question

Beyond genomic-integration risks, a second concern has been raised about bacterial origins of replication in vaccine plasmids: cryptic mammalian promoter activity that creates biological activity without genomic integration.

Lemp et al. 2012

Lemp et al. demonstrated that ColE1 / pUC origins - exactly the bacterial origins used in vaccine plasmids - contain cryptic mammalian promoters that drive read-through transcription (Nucleic Acids Research 2012, PMID 22618870, DOI 10.1093/nar/gks451). [AN] CONFIDENCE: MODERATE for the molecular-biology finding itself. Key results:

• ColE1 / pUC bacterial origins contain cryptic promoter sequences.
• These promoters are active in mammalian cells.
• They drive transcription of downstream sequences.
• No genomic integration required; episomal expression is sufficient.

Human RNA-Seq signal

Ryan et al. performed RNA-Seq analysis on blood from vaccinated individuals and reported elevated coverage over the ori region (bp 2890-3478) - the location where Lemp identified cryptic promoter activity. This finding was circulated via investigator commentary (McKernan Substack, December 2024) but is not yet independently peer-reviewed. [CM] CONFIDENCE: LOW . The signal is hypothesis-generating; replication in independent labs is needed.

Why this matters for genomic defense

Both can in principle drive unintended gene expression from residual plasmid DNA. [MECHANISTIC] CONFIDENCE: LOW-MODERATE for the dual-pathway model. Clinical significance in vaccinated humans is not established.

Regulatory gap

Current regulatory assessments assume that without integration, residual DNA is inert. The cryptic-promoter data challenge that assumption at the molecular level. Whether the resulting expression is clinically meaningful is a separate question that has not been answered.

Source: Lemp et al. 2012 (PMID 22618870). Ryan et al. RNA-Seq analysis: investigator commentary (McKernan Substack, December 2024), not peer-reviewed.

Part 5: Biomarker tracking

Tracking biomarkers over time provides a window into mutagen exposure, genomic damage, detox capacity, and autophagic activity. Repeat every 8-12 weeks while symptoms evolve or during intervention protocols. Look for directional trends, not single numbers.

Many biomarkers below are research-grade or available only through specialty labs. Absence of testing does not mean absence of risk; trends and symptoms still matter clinically.

Clinical decisions belong with the clinician; this is informational context only.

Part 6: Protocol summary

Evidence-based strategies for genomic defense.

Practical implementation

Food-first baseline. Cruciferous vegetables (1-2 cups daily, chopped and rested 10 min before cooking), allium vegetables daily, berries (1 cup), green tea (2-3 cups), spices (turmeric with black pepper, rosemary, ginger).

Cooking methods. Marinate meats with rosemary, garlic, lemon juice (reduces HAA formation substantially); avoid charring; use moist heat (poaching, steaming, stewing) which produces fewer mutagens.

Tier 1 - Core defense (most adults): curcumin with piperine or liposomal 500-1000 mg daily, broccoli sprout extract 400-600 micromol, green tea extract 400 mg.

Tier 2 - Enhanced detox (high mutagen exposure): chlorophyllin 100 mg TID, quercetin 500 mg, resveratrol 200-500 mg.

Tier 3 - Autophagy support (post-viral, spike persistence): spermidine 1-3 mg, 14-16 hour daily fasting window OR 5-day fast-mimicking diet monthly, consider low-dose rapamycin under clinician.

Work with a clinician familiar with these protocols, especially with existing conditions or medications. Monitor biomarkers before and during.

Part 7: Cardiac-specific considerations

2024-2025 research documents cardiac-specific manifestations of spike protein persistence that warrant targeted monitoring.

Subclinical myopericarditis

McCullough et al. 2025 review persistent spike protein accumulation in cardiac tissue, subclinical inflammation, micro-scarring detectable by cardiac MRI with late gadolinium enhancement, and presentations that may include cardiac arrest with no premonitory symptoms (Med Reconcil Appl 2025). [PP + SR] CONFIDENCE: LOW-MODERATE (review, mixed evidence base).

Histopathologic spectrum on endomyocardial biopsy and autopsy

A Japanese multicenter series (Circulation Journal, PMID 39496392) examined 40 patients with clinically diagnosed post-mRNA myocarditis who underwent endomyocardial biopsy or autopsy. 47.5% had mild lymphocytic infiltration with interstitial edema but without cardiomyocyte injury; 52.5% had cardiomyocyte injury (lymphocytic, eosinophilic, or mixed). Cardiomyocyte injury was strongly linked to clinical severity: 71% of the injury group developed fulminant myocarditis versus 0% in the no-injury group (Circulation Journal 2024, PMID 39496392). [PP] CONFIDENCE: MODERATE . This is the strongest histopathological evidence that the injury spectrum is bimodal: many cases show inflammation without myocyte damage, but when myocyte damage is present, fulminant courses cluster.

Autopsy series in fatal cases

Hulscher, McCullough and colleagues conducted a systematic review of autopsy findings in 28 cases of fatal COVID-19 vaccine-induced myocarditis (ESC Heart Failure 2024, PMID 38221509). Cardiovascular findings predominated; temporal association was a median of roughly 3-6 days post-vaccination; causality was assessed as likely or confirmed in the reviewed cases. [PP + SR] CONFIDENCE: LOW-MODERATE (selection bias inherent to fatal-case ascertainment). Note: a broader systematic review by the same group covering deaths after COVID-19 vaccination generally was withdrawn at the request of the Editors-in-Chief of the Journal of Clinical Medicine; the myocarditis-specific paper above remains available on PubMed.

Important counter-evidence on troponin screening

Albertson et al. 2024 (PMID 38489117, Infect Dis Ther; a Pfizer-sponsored prospective study) measured serum troponin I in thousands of participants aged 5-30 years before and after BNT162b2 vaccination, with a placebo comparator. Elevated troponin was uncommon (at or below 1.0%) and occurred at similar rates before vaccination, 4 days post-dose, and 1 month later. Findings were comparable between vaccine and placebo recipients, with no cases of myocarditis or pericarditis reported. The authors concluded there was no evidence that BNT162b2 causes troponin elevations indicative of subclinical myocardial injury. [PR] CONFIDENCE: MODERATE .

A subsequent Letter to the Editor (PMID 40193006) critiqued the methodology and interpretation. [CM] CONFIDENCE: LOW .

This counter-evidence matters: this was a study specifically designed to look for subclinical signal and found none. Routine troponin screening in asymptomatic vaccinated individuals is not endorsed by this study. Selected symptomatic cohorts may warrant monitoring based on other data (Barmada, Warren, Buergin etc.), but extrapolating from clinically diagnosed myocarditis cases to asymptomatic populations is not supported by Albertson.

A second large troponin study, Pfeiffer et al. (Moderna-sponsored phase 4 RCT, Open Forum Infectious Diseases 2026, DOI 10.1093/ofid/ofag139) used a randomised, placebo-controlled, observer-blind, crossover design in roughly 1,000 healthy participants aged 12-30 years at 24 US sites, comparing mRNA-1273.712 50 microgram versus placebo 28 days apart. cTnI elevations were infrequent (about 1.8% had any elevation), similar after vaccine versus placebo, often linked to physical activity, and occurred without myocarditis or pericarditis symptoms or diagnoses. Funding disclosure: Moderna-sponsored. [PR] CONFIDENCE: MODERATE (industry-funded; placebo-controlled design is robust, but sponsorship is a known source of bias in adverse-event reporting and should be weighed accordingly).

Profibrotic myeloid response

Barmada et al. 2023 in Sci Immunol described "cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response" in SARS-CoV-2 mRNA vaccine-associated myocarditis (DOI 10.1126/sciimmunol.adh3455). [PR] CONFIDENCE: MODERATE . Fibrosis creates permanent tissue remodeling that autophagy alone cannot reverse.

Risk stratification

• Buergin et al. 2023 (Eur J Heart Fail): young males (especially 18-25 years) at highest risk for vaccine-associated myopericarditis.
• Krug et al. 2022 (Eur J Clin Invest): risk-benefit analysis suggested risks exceeded benefits for some demographics in some windows.
• Cavalli et al. 2025 (NPJ Vaccines): GWAS identified HLA haplotypes associated with myocarditis / pericarditis following COVID-19 vaccination.

Cardiac mitigation (investigational)

• Colchicine (Valore et al. 2023, Front Cardiovasc Med): case report of successful mRNA-1270 vaccine-associated myopericarditis treatment. Inhibits microtubule polymerisation.
• Rapamycin case study (Hulscher et al. 2024): resolution of refractory COVID-19 vaccine-induced myopericarditis with adjunctive rapamycin. First documented human case supporting mTOR inhibition for persistent spike-related cardiac injury.
• Nattokinase + bromelain + curcumin (McCullough et al. 2023): proposed combination. Nattokinase is fibrinolytic; bromelain is proteolytic; curcumin is anti-fibrotic.

Related: Spike-Related Injury Support for enzymatic fibrinolytics, The Slow Burn, Fasting & Autophagy, Amyloid Fibrin Microclots for the fibrinaloid mechanism.

Mid- to long-term outcomes and imaging follow-up

Longitudinal cohort data is now accumulating and shows a mixed picture: clinical symptoms usually resolve, but imaging abnormalities persist in a meaningful fraction.

• MACiV multicenter study (US, eClinicalMedicine / Lancet 2024, PMID 39290640). Roughly 300 young patients with vaccine-associated myocarditis. LGE present in 82% at baseline and persisted in 60% at a median follow-up of about 178 days. No cardiac deaths or transplants were reported; mid-term clinical outcomes were favourable, but the imaging persistence warrants surveillance. [PP] CONFIDENCE: MODERATE .
• Norwegian nationwide long-term follow-up (Open Heart 2025, PMID 42082376). At a mean of roughly 2 years post-vaccine myocarditis, mostly normal cardiac function, biomarkers, ECG, and arrhythmia burden versus controls. Higher rate of discrete LGE (43% vs 22%) and slightly worse global longitudinal strain, but clinical significance is uncertain. [PP] CONFIDENCE: MODERATE .

The pattern across these cohorts: clinical recovery is the norm, gross cardiac function is preserved, but focal LGE persistence on CMR is common (60-82% at months of follow-up). Whether this represents subclinical fibrosis with late clinical consequence or a radiological finding without functional impact is unresolved and is the principal open question for long-term surveillance.

Clinical decisions belong with a cardiologist.

Part 8: Mast-cell stabilisation

2024-2025 research documents mast-cell activation as a parallel inflammatory pathway in some post-vaccination and Long COVID presentations.

The mast-cell / spike connection

Spike protein activates mast cells via MRGPRX2 receptor engagement, Fc-epsilon-RI receptor cross-linking, and TLR4 pathway activation. Mast-cell mediators drive symptoms in some patients: histamine (flushing, headaches, tachycardia), tryptase (tissue remodeling, fibrosis), MMP-9 (blood-brain barrier disruption), VEGF (vascular permeability), IL-6 / TNF-alpha (systemic inflammation). Mast cells reside at blood-brain barrier, gut epithelium, cardiovascular system, and skin. [MECHANISTIC + PP] CONFIDENCE: LOW-MODERATE .

Luteolin versus cromolyn

Tsiloni et al. 2024 ("Luteolin Is More Potent than Cromolyn in Their Ability to Inhibit Mediator Release from Cultured Human Mast Cells") reported that luteolin was significantly more potent than cromolyn at inhibiting histamine, tryptase, MMP-9, and VEGF release from cultured human mast cells, effective against both allergic and non-allergic stimulation (Int Arch Allergy Immunol 2024). [AN] CONFIDENCE: MODERATE for the in vitro comparison.

Dosing: 100-200 mg daily (liposomal preferred for bioavailability). Cromolyn is prescription with poor systemic absorption; luteolin offers better bioavailability.

Baicalein: anti-spike plus mast-cell stabilisation

Baicalein shows dual mechanisms in preclinical work: direct anti-spike activity via 3CL protease inhibition and spike-protein interaction modulation, plus mast-cell stabilisation via inhibition of IgE-mediated mediator release (PMC 2024). [AN + MECHANISTIC] CONFIDENCE: LOW-MODERATE .

See the Baicalin article for Nrf2 / ARE activation, AMPK stimulation, mTOR inhibition, and Drp1-mediated mitochondrial dynamics. Dosing: 200-600 mg daily of standardised Scutellaria baicalensis extract. The aglycone baicalein is more bioavailable than the glucuronide baicalin for systemic effects.

Supporting stabilisers

Practical protocol

Tier 1 - Core: luteolin (liposomal) 100-200 mg, quercetin 500 mg with vitamin C, vitamin C 1000 mg.

Tier 2 - Enhanced: add baicalein 200-400 mg.

Tier 3 - Senolytic: add fisetin 100-500 mg; consider fasting protocols for natural senolytic effect.

Drug interactions: flavonoids interact with CYP450 enzymes. Work with a clinician if on medications. Discontinue before surgery.

Part 9: Integrated defense

Three-layer framework.

• Layer 1 (Systemic): classic mutagen detox, autophagy activation, mTOR modulation.
• Layer 2 (Cardiac): diagnostic monitoring in symptomatic individuals, anti-fibrotic support, proteolytic clearance, rapamycin proof-of-concept (case report only).
• Layer 3 (Mast cell): luteolin (more potent than cromolyn in vitro), baicalein (anti-spike + stabilisation in preclinical models), quercetin / fisetin / vitamin C synergy.

Stratified summary

Evidence hierarchy

• High confidence (RCTs / strong mechanistic): chlorophyllin 55% reduction; broccoli sprouts 61% increase; luteolin more potent than cromolyn in vitro; autophagy via fasting; ATBC and SELECT negative findings.
• Moderate (small RCTs, case series, mechanistic): rapamycin resolves myopericarditis (1 case); nattokinase degrades spike in cultured cells; baicalein inhibits 3CL and stabilises mast cells; mTOR / p53 dysregulation.
• Low (preliminary, hypothesis-generating): population-level cancer risk; optimal mTOR timing; long-term outcomes; prevalence in the general vaccinated population.

Where evidence is preliminary or mechanistic, this article states so explicitly. High-confidence interventions are prioritised.

Part 10: Open questions

• Spike persistence duration. How long can spike remain in tissues? What determines clearance versus persistence?
• mTOR inhibition timing. Optimal window after COVID / vaccination? Early inhibition may aid viral clearance; chronic inhibition may help with persistent antigen.
• Patient stratification. Who benefits from autophagy induction?
• Combination therapies. mTOR inhibitors + autophagy inducers + fibrinolytics?
• Long-term outcomes. Cancer risk with chronic spike persistence and mTOR activation?

2025-2026 trial landscape

Several trials are exploring low-dose rapamycin for Long COVID and post-vaccination syndromes, spermidine-rich diets for post-viral fatigue, combination approaches, and biomarker-guided protocols using LC-MS/MS spike detection. Mechanistic rationale is strong; clinical outcome data are still pending.

Counter-evidence and methodological limits

Several findings qualify the framework above:

• Albertson et al. 2024 (PMID 38489117; Pfizer-sponsored, placebo-controlled, n = thousands, ages 5-30) was specifically designed to detect subclinical troponin elevation after BNT162b2 vaccination and found no signal: elevations were at or below 1.0% in both vaccine and placebo arms at all timepoints. Routine troponin screening in asymptomatic vaccinated individuals is not endorsed by this study.
• Duncan et al. 2024 (AIDS) found no significant changes in HIV viremia or reservoir size post-vaccination in fully suppressed PLWH.
• The mTOR / p53 mechanism is biologically plausible but not yet demonstrated end-to-end in human tissue.
• Supplement bioavailability varies widely; formulation matters.
• Many biomarkers listed are research-grade and not widely available.
• Population-level cancer-risk data following widespread vaccination are still being collected; ecological signals are confounded by age, comorbidity, screening changes, and pandemic-era delays.

Sources

Classic mutagen defense (peer-reviewed)

• Egner PA et al., PNAS 2001 - chlorophyllin / aflatoxin, PMID 11724948
• Egner PA et al., Cancer Prev Res 2014 - broccoli sprouts / benzene, PMID 24913818
• ATBC, NEJM 1994 - beta-carotene harm in smokers, PMID 8127329
• Cole BF et al., JAMA 2007 - folic acid / adenoma, PMID 17551129
• SELECT, JAMA 2008 - vitamin E no cancer benefit, PMID 19066370

Spike persistence and mTOR / p53 (2025-2026)

• Melo SS et al., Viruses 2025 - mTOR / p53 axis and spike persistence, PMID 40431629
• PMID 40358138 - spike in CD16+ monocytes up to 245 days post-vaccination
• Nature 2025 - TENT5A re-adenylation of vaccine mRNA, DOI 10.1038/s41586-025-08842-1
• Isidoro et al., Cancers 2025 - EGFR / mTOR pro-carcinogenic effects
• Zhai et al., MedComm 2025 - ACE2 / TLR4 / ER insulin signaling disruption, PMID 41190280
• Ota Y et al., J Clin Neurosci 2025 - spike in cerebral arteries 17 months, PMID 40184822
• Peluso et al. 2023 - gut lymphoid tissue persistence, PMID 37689208
• Matveev et al., iScience 2023 - HIV reservoir in unsuppressed PLWH
• Duncan et al., AIDS 2024 - no reservoir change in suppressed PLWH

Cryptic promoter and DNA contamination

• Lemp et al., Nucleic Acids Research 2012 - ColE1 cryptic promoter, PMID 22618870
• Speicher et al., Autoimmunity 2025 - residual plasmid DNA / SV40 analysis, PMID 40913499

Cardiac

• McCullough et al. 2025 - persistent spike cardiac review
• Japanese multicenter EMB / autopsy series - histopathologic spectrum, Circulation Journal 2024, PMID 39496392
• Hulscher, McCullough et al. - 28-case fatal myocarditis autopsy systematic review, ESC Heart Failure 2024, PMID 38221509
• Albertson et al. 2024 - Pfizer-sponsored placebo-controlled troponin study in 5-30 yos post-BNT162b2, n = thousands, PMID 38489117 (no subclinical elevation signal found)
• Pfeiffer et al. 2026 - Moderna-sponsored phase 4 RCT troponin study in 12-30 yos post-mRNA-1273, n ~ 1,000, DOI 10.1093/ofid/ofag139 (no subclinical elevation signal found; industry-funded)
• Letter re Albertson 2024, PMID 40193006
• Barmada et al., Sci Immunol 2023 - profibrotic myeloid response
• Hulscher et al. 2024 - rapamycin myopericarditis case
• Buergin et al., Eur J Heart Fail 2023 - demographic risk
• Krug et al., Eur J Clin Invest 2022 - risk-benefit analysis
• Cavalli et al., NPJ Vaccines 2025 - GWAS / HLA haplotypes
• Valore et al., Front Cardiovasc Med 2023 - colchicine case report
• Chiu et al., Eur J Pediatr 2023 - ECG in adolescents, PMID 36602621
• Warren et al., Open Heart 2025 - cardiac MRI LGE findings
• MACiV multicenter - vaccine-associated myocarditis in the young, eClinicalMedicine 2024, PMID 39290640
• Norwegian nationwide long-term follow-up, Open Heart 2025, PMID 42082376

Mast cell

• Tsilioni et al., Int Arch Allergy Immunol 2024 - luteolin more potent than cromolyn in vitro
• PMC 2024 - baicalein anti-spike activity
• Viruses 2021 - immunonutrition review
• Front Immunol 2024 - mast-cell review

Autophagy and mTOR

• Eisenberg et al., Nat Med 2016 - spermidine / autophagy, PMID 27841876

Systematic reviews

• Ferguson LR, Annu Rev Nutr 2008
• Fong LYY, Nutrients 2021
• Banerjee S, Antioxidants 2020

Related posts

• Amyloid Fibrin Microclots in Long COVID: Evidence Review and Treatment Landscape - the full fibrinaloid mechanism and Edogawa Clinical Pathway.
• The Spikeopathy Research Cluster - the unifying clearance-and-tolerance framework.
• The Slow Burn, Part 1: Spike Persistence and Microclots.
• Spike-Related Injury Support: Evidence Snapshot and Cautions.
• Critical Research Gaps: DNA Contamination.
• Fasting & Autophagy.
• Baicalin.
• Methodology - how this article's evidence tags work.

TL;DR

The strongest mechanistic evidence for spike-driven clotting pathology is Ryu et al. 2024 in Nature: spike protein binds the fibrinogen alpha chain and produces dense, fibrinolysis-resistant structures. An experimental antibody (5B8) reversed the effect in mouse models. [PR] CONFIDENCE: HIGH for the mechanism.

For interventions, nattokinase degrades spike protein in cultured cells (Kageyama et al. 2022, bioRxiv preprint), but no large human trials exist for Long COVID or vaccine injury. NAC showed no mortality benefit in a Brazilian ICU RCT (De Alencar 2021). Curcumin and quercetin lower inflammatory markers in small COVID trials, but clinical endpoints are inconsistent. DFPA is a hospital-based extracorporeal option with established procedural components but no RCT-level outcomes for the combined DFPA + SHED pathway in PASC.

Major health agencies do not endorse any of these compounds for COVID-19 or vaccine adverse events. Most of the evidence sits at the "promising in vitro, speculative in humans" end of the spectrum. Anyone experimenting needs medical supervision and lab monitoring because many of these agents thin blood or interact with medications.

Evidence gradient: In vitro → Case series → Pilot RCT → Large RCT / Meta-analysis. Most of what follows lives on the left side of that curve.

The problem: fibrinaloid microclots and persistent spike

Two peer-reviewed findings drive this field.

Spike binds fibrinogen directly. Ryu et al. (2024, Nature) localised the binding site on the fibrinogen alpha chain and showed the interaction is necessary for much of spike's thromboinflammatory effect in mouse models; antibody 5B8 blocked it. [PR] CONFIDENCE: HIGH . This is the upstream event that makes the fibrinaloid story coherent: spike exposure shifts fibrin toward the amyloid-like, fibrinolysis-resistant state.

Source: Ryu et al. 2024, Nature.

Fibrinaloid microclots circulate in PASC patients. Separate proteomic and microscopy work from Pretorius, Kell and colleagues characterised amyloid-like fibrin microclots in Long COVID plasma that trap inflammatory proteins and resist fibrinolysis. The terminology was formalised in Kell & Pretorius 2022 (Biochem J 479:537, DOI 10.1042/BCJ20210825): "fibrinaloid" (fibrin + amyloid). [PP + MECHANISTIC] CONFIDENCE: MODERATE for the patient-cohort detection.

Sources: Pretorius et al. 2021, Cardiovasc Diabetol; Kell & Pretorius 2022, Biochem J.

Put the two findings together and you get a coherent mechanism: persistent spike protein drives persistent fibrinaloid clotting, which plausibly explains symptoms from brain fog to exercise intolerance. Clinical consensus on treatment does not yet exist. The literature is a patchwork of in vitro studies, small pilot trials, observational reports, and a small number of investigator-led clinical programmes. Definitive answers are thin on the ground.

For the full mechanism, patient-cohort evidence, and the Edogawa clinical pathway discussion, see the Amyloid Fibrin Microclots review.

Why spike persists: the cellular survival mechanism

Before diving into specific interventions, it is worth understanding why spike protein may persist for months instead of being cleared normally. This mechanism has direct implications for which protocols may be effective.

The mTOR / p53 survival pathway

Melo et al. (2025, Viruses, PMID 40431629) propose that SARS-CoV-2 spike protein activates mTOR (mechanistic target of rapamycin) while simultaneously inhibiting p53, the cell's "guardian of the genome":

• mTOR activation promotes cell growth, protein synthesis, and metabolic reprogramming, keeping the cell "alive and productive."
• p53 inhibition blocks apoptosis (programmed cell death) and DNA damage responses, preventing the cell from self-destructing.
• Net result: cells that should die continue to survive and produce spike protein.

[MECHANISTIC] CONFIDENCE: MODERATE for the pathway; the proposal is convergent inference from molecular evidence, not yet directly demonstrated end-to-end in human tissue.

Source: Melo et al. 2025, Viruses, PMID 40431629.

Human evidence of persistence

This mechanistic framework is supported by human detection studies:

• Ota et al. (2025): spike protein detected in cerebral arteries of haemorrhagic stroke patients 17 months post-vaccination, longest documented persistence in human brain vasculature (J Clin Neurosci, PMID 40184822). [AUTOPSY] CONFIDENCE: MODERATE .
• Patterson et al.: S1 sub-units of spike protein found in monocytes up to 15 months post-infection. [PP] CONFIDENCE: LOW-MODERATE .
• Bhattacharjee 2025 (preprint): circulating spike detected up to 709 days post-vaccination in a subset of individuals with post-vaccination syndrome. [PP] CONFIDENCE: LOW (preprint, small subset).
• Stein et al. 2022, Nature: SARS-CoV-2 RNA identified in multiple tissue beds at autopsy, 7+ months post-infection (PMID 36517603). [AUTOPSY] CONFIDENCE: MODERATE .

Why this matters for protocols

The mechanism suggests that mTOR inhibition combined with p53 pathway support could help clear persistent spike-producing cells.

mTOR inhibition strategies:

• Rapamycin (sirolimus): most potent mTOR inhibitor; case reports of resolution of refractory myopericarditis. Prescription-only; immunosuppressive; requires monitoring.
• Spermidine: natural mTOR inhibitor via EP300 inhibition; induces autophagy. Available as a supplement.
• Fasting protocols: 14-16 hour daily windows or 5-day fast-mimicking diets. General autophagy literature is robust; spike-specific evidence is not.

p53 pathway support:

• Nrf2 activators (baicalin, curcumin, broccoli sprouts / sulforaphane): support DNA damage response.
• Antioxidants: reduce oxidative stress that can impair p53 function.
• Autophagy enhancers: clear cells that should have undergone apoptosis.

Clinical relevance

The mTOR / p53 mechanism could explain both (1) viral reservoirs after infection and (2) prolonged spike production after vaccination in a subset of recipients. It creates a rational basis for mTOR-targeted interventions but is not yet proven at population level. Long-term epidemiological data are still needed.

Evidence snapshot

Enzymatic fibrinolytics

The hypothesis is straightforward: proteolytic enzymes like nattokinase and lumbrokinase may degrade fibrinaloid microclots and cleave spike protein fragments. Nattokinase, sourced from Bacillus subtilis in fermented soy, has documented fibrinolytic activity and boosts endogenous plasmin generation in animal models (Urano et al. 2006). [AN] CONFIDENCE: MODERATE .

More relevant to spike: Kageyama et al. 2022 (bioRxiv preprint) reported nattokinase degrading SARS-CoV-2 spike protein in cultured cells. [AN] CONFIDENCE: LOW-MODERATE (preprint, not yet peer-reviewed). It remains one of the few direct spike-degradation findings available.

Sources: Urano et al. 2006, J Thromb Haemost; Kageyama et al. 2022, bioRxiv (preprint).

MMP-9 and blood-brain barrier breakdown (2024)

SARS-CoV-2 spike protein stimulates human microglia to release matrix metalloproteinase-9 (MMP-9), which is elevated in Long COVID patients; MMP-9 degrades tight junction proteins and directly contributes to blood-brain barrier breakdown (Kempuraj et al. 2024, PMID 39403255). [PP + MECHANISTIC] CONFIDENCE: MODERATE .

This creates an additional rationale for MMP-9 inhibitory compounds:

• EGCG (green tea catechins): documented MMP-9 inhibition via NF-kB pathway.
• Curcumin: downregulates MMP-9 expression through multiple pathways.
• Quercetin: reduces MMP-9 production in inflammatory conditions.
• Resveratrol: modulates MMP-9 activity via SIRT1 pathways.

These polyphenols may provide dual benefit: anti-inflammatory activity plus MMP-9-specific neuroprotection. Clinical translation in PASC remains untested.

What is missing

Large human trials. For Long COVID, vaccine injury, or post-viral syndromes, the clinical evidence does not exist yet. Dosing gets extrapolated from cardiovascular supplement studies, often 2,000 FU (fibrinolytic units) once or twice daily for nattokinase. Product quality and potency vary across brands.

The risks are real: these enzymes interact with anticoagulants, create bleeding risks during surgery, and can cause problems in people with bleeding disorders. Mechanistic plausibility is there. Clinical benefit remains unproven. Anyone claiming "microgram-level clearance" or "integration reversal" is selling, not reporting.

Polyphenols and anti-inflammatory nutrients

Curcumin, quercetin, resveratrol, pomegranate extract, and EGCG work on downregulating NF-kB / STAT3 signalling, blunting platelet activation, and supporting endothelial health. Small RCTs in acute COVID suggest curcumin or quercetin combinations can reduce CRP, ferritin, and hospitalisation time (Sadeghi et al. 2021; Peter et al. 2021). Sample sizes under 150. Outcomes variable. [PR] CONFIDENCE: LOW-MODERATE .

Sources: Sadeghi et al. 2021, Nutrients; Peter et al. 2021, Phytother Res.

Resveratrol activates sirtuin pathways and mitochondrial biogenesis in animal models (Lagouge et al. 2006), but bioavailability is notoriously poor. High doses interact with anticoagulants (curcumin) or CYP enzymes (quercetin). Polyphenols are reasonable adjuncts for general cardiometabolic health. Claims of reversing spike pathology rest on extrapolation, not direct evidence.

Thiol donors and redox support

NAC, alpha-lipoic acid, glycine, selenium, and iodine focus on glutathione restoration and redox balance. NAC has the strongest data, and it is not great: a Brazilian RCT with 135 ICU patients found no significant mortality difference, though it was well tolerated (De Alencar et al. 2021). [PR] CONFIDENCE: MODERATE for the null result.

Source: De Alencar et al. 2021, Clin Infect Dis.

NAC's relevance to spike mechanisms

• Ferroptosis inhibition: NAC may counteract spike-induced microglial ferroptosis (the miR-204 / ACSL4 pathway is documented in HIV Tat research and is plausibly conserved).
• Disulfide bond disruption: NAC breaks disulfide bonds in protein aggregates, potentially aiding spike clearance.
• Glutathione precursor: replenishes the body's master antioxidant, which is depleted in COVID and spike exposure.
• CFTR support: NAC has mucolytic properties that may support CFTR function compromised by spike-induced TGF-beta activation.

For detailed NAC mechanisms and research, see the NAC (N-Acetylcysteine) research review.

IV NAC carries rare hypersensitivity risks and can interact with nitroglycerin. Oral NAC is generally well tolerated.

Adjuncts you will hear mentioned

Methylene blue with vitamin C shows up in experimental protocols for neurovascular symptoms. Tan et al. published a case series in 2023 (Clin Neuropharmacol). Screening is essential: G6PD deficiency, SSRIs, and serotonergic drugs create real toxicity risks. [PP] CONFIDENCE: LOW (small series).

Triple anticoagulant / antiplatelet therapy. Pretorius and colleagues reported improvement with combination regimens (low-dose heparinoids plus antiplatelet agents) in South African cohorts. Data are observational and off-label; bleeding risk is non-trivial. [PP] CONFIDENCE: LOW-MODERATE .

Taurine and magnesium get mentioned for cellular osmoregulation and energy metabolism cofactors. The evidence there is general wellness, not spike-specific.

Microbiome and lifestyle support

Lactobacillus reuteri ATCC PTA 6475 shows up in protocols for oxytocin modulation and gut barrier integrity. Antunes et al. published small human trial data in 2022 (Brain Behav Immun Health). No direct spike data exists. Fermented foods and fibre help lower endotoxin load and improve metabolic markers: prudent for cardiometabolic risk, untested for fibrinaloid microclots.

Neuroprotective compounds with spike-relevant mechanisms

Lion's Mane mushroom (Hericium erinaceus):

• NGF and BDNF support: promotes nerve growth factor and brain-derived neurotrophic factor, potentially counteracting spike-associated hippocampal changes.
• Neuroinflammation reduction: documented anti-inflammatory effects in brain tissue.
• Cognitive support: may aid recovery from spike-associated cognitive impairment ("brain fog").

For detailed research, see the Lion's Mane mushroom benefits review.

Oregano (Origanum vulgare) - carvacrol and thymol:

• MMP-9 inhibition: carvacrol downregulates MMP-9 expression, plausibly protecting blood-brain barrier integrity.
• Antimicrobial properties: may support microbiome balance.
• Anti-inflammatory effects: reduces pro-inflammatory cytokines elevated in Long COVID.

For detailed research, see the Oregano benefits review.

Movement (low-intensity, below symptom threshold for PEM patients), sleep hygiene, and paced breathing have evidence backing for autonomic recovery and vascular health. Boring, but they work.

Hospital-based option: double filtration plasmapheresis (DFPA)

Beyond supplements and lifestyle, the most aggressive spike-clearance approach currently in clinical use is double filtration plasmapheresis (DFPA), an established apheresis procedure that removes plasma constituents directly. DFPA is used at Edogawa Hospital (Tokyo) as part of a hospital-led programme combining apheresis with SHED-conditioned medium (dental-pulp MSC secretome). The components are real; the combined pathway outcomes are preliminary.

[PR + INV] CONFIDENCE: LOW-MODERATE for the combined DFPA + SHED pathway in PASC. Procedural components themselves (the apheresis step) are [ESTABLISHED] CONFIDENCE: HIGH as a class.

The full mechanism discussion, the McCairn n=38 preliminary biomarker data, the SCGF/SGF terminology clarification, and the author case report (patient 40) are documented in the Amyloid Fibrin Microclots review - Edogawa Clinical Pathway section. DFPA is not a home intervention, not a supplement, and not available outside specialised centres.

Monitoring and laboratory markers

Anyone experimenting with these protocols should track coagulation and inflammatory markers with a qualified clinician. Baseline labs suggested by the thromboinflammation literature:

• CBC, CMP
• Fibrinogen, D-dimer
• Ferritin, hs-CRP
• Lipid panel, homocysteine
• Vitamin D, thyroid function

Advanced diagnostics exist (viscoelastic testing, fluorescence microscopy for microclots via the Synaptek smear protocol), but availability is limited and this is not standard of care. The International Society on Thrombosis and Haemostasis (ISTH) recommends risk-stratified anticoagulation in COVID-19 and emphasises monitoring D-dimer trends (Thachil et al. 2020).

Source: Thachil et al. 2020, J Thromb Haemost.

Regulatory reality check

Major health agencies do not endorse enzyme supplements or nutraceutical stacks for COVID-19 or vaccine adverse events. This includes WHO, CDC, and EMA. Integrative and functional medicine clinics may offer protocols, but most rely on extrapolated data. Documentation should include informed consent and lab monitoring.

Spontaneous adverse event reporting systems (VAERS, Yellow Card, EudraVigilance) capture suspected reactions. They do not confirm causality. Anyone citing these systems as definitive proof of harm needs a statistics refresher: a signal is a hypothesis-generating event, not a finding.

What the evidence actually shows

Mechanistic signals for spike-driven fibrinaloid microclots are robust. The Ryu et al. Nature paper on spike-fibrinogen binding is solid. The microclot observations in Long COVID patients are replicated across multiple groups. But therapeutics remain experimental outside clinical trials.

Enzymatic fibrinolytics show promising lab data. Nattokinase degrades spike in cultured cells. Clinical outcomes in PASC are missing. Use cautiously if you are on anticoagulants.

Polyphenols, NAC, and omega-3s have supportive evidence for lowering inflammatory markers. They do not have definitive proof of reversing spike-related injury. The distinction matters.

mTOR inhibitors (rapamycin, spermidine) and fasting protocols are mechanistically rational in light of Melo et al. 2025, but clinical translation is early. Rapamycin is prescription-only and immunosuppressive.

DFPA + SHED is the most aggressive option, hospital-only, with preliminary cohort biomarker data but no RCT-level outcomes.

Monitoring is non-negotiable. Documented risks are real: bleeding, drug interactions, metabolic effects. "Natural" does not mean benign.

Selected references

1. Ryu W, et al. Nature. 2024;628:534-541. Crystal structure of SARS-CoV-2 spike protein complexed with fibrinogen and the protective effect of antibody 5B8. doi:10.1038/s41586-024-07873-4
2. Pretorius E, et al. Cardiovasc Diabetol. 2021;20:172. doi:10.1186/s12933-021-01359-7
3. Kell DB, Laubscher GJ, Pretorius E. Biochem J. 2022;479(4):537-559. A central role for amyloid-like fibrin in Long COVID and the fibrinaloid phenotype. doi:10.1042/BCJ20210825 (PMID 35195253)
4. Melo SS, et al. Viruses. 2025. mTOR / p53 axis and spike persistence. PMID 40431629
5. Ota Y, et al. J Clin Neurosci. 2025. Spike in cerebral arteries 17 months post-vaccination. PMID 40184822
6. Stein SR, et al. Nature. 2022. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. PMID 36517603
7. Kempuraj D, et al. 2024. Long COVID elevated MMP-9 and release from microglia by SARS-CoV-2 spike protein. PMID 39403255
8. Urano T, et al. J Thromb Haemost. 2006;4(2):381-388. doi:10.1111/j.1538-7836.2006.01974.x
9. Kageyama Y, et al. bioRxiv. 2022. Nattokinase degrades SARS-CoV-2 spike in cultured cells. doi:10.1101/2022.07.11.499636 (preprint, not peer-reviewed)
10. De Alencar JCG, et al. Clin Infect Dis. 2021;72(11):e364-e371. NAC in severe COVID RCT. doi:10.1093/cid/ciaa1443
11. Sadeghi A, et al. Nutrients. 2021;13(6):2086. Curcumin in COVID. doi:10.3390/nu13062086
12. Peter E, et al. Phytother Res. 2021;35(11):6174-6182. Quercetin in COVID. doi:10.1002/ptr.7053
13. Tan Y, et al. Clin Neuropharmacol. 2023;46(2):45-53. Methylene blue case series. doi:10.1097/WNF.0000000000000544
14. Antunes LC, et al. Brain Behav Immun Health. 2022;24:100545. L. reuteri and oxytocin trial. doi:10.1016/j.bbih.2022.100545
15. Thachil J, et al. J Thromb Haemost. 2020;18(5):1023-1026. ISTH COVID-19 anticoagulation guidance. doi:10.1111/jth.14866

For DFPA, SHED-conditioned medium, and the Edogawa clinical pathway, see the Amyloid Fibrin Microclots review source list.

Related posts

• Amyloid Fibrin Microclots in Long COVID: Evidence Review and Treatment Landscape - the full fibrinaloid mechanism, patient-cohort evidence, and the Edogawa Clinical Pathway.
• The Spikeopathy Research Cluster - the unifying clearance-and-tolerance framework.
• The Slow Burn, Part 1: Spike Persistence and Microclots.
• NAC (N-Acetylcysteine): Comprehensive Research Review.
• Lion's Mane Mushroom: Cognitive Enhancement & Neuroprotection.
• Methodology - how this article's evidence tags work.